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1INTRODUCTION
Diabetes Mellitus(DM) has topped the leading health related
catastrophes the world ever witnessed(1). By 2040,the prevalence of
diabetics globally would raise to 642 million(2).India leads the world in
diabetic population and estimated to have 62.4 million people with
diabetes, and 77.2 million with prediabetes (3). It is predicted that by
2030, in India, DM may affect up to 79.4 million(4). Hence WHO has
labeled India as the diabetic capital of the world.
The total health burden due to DM is mainly by the severity of
diabetic complications in different organs. Diabetic retinopathy(DR)
affects more than 93 million people worldwide(5).DR is the most
frequent cause of preventable blindness in middle aged population.
However, recently in diabetic patients ocular surface problems,especially
dry eye have been gaining attention.
Various corneal components like the epithelium, endothelium,
nerves and immune cells signify specific systemic complications of
diabetes. Just as diabetic retinopathy stands as a marker of more
generalized microvascular disease, corneal neuropathy can act as a tool to
predict peripheral and autonomic neuropathy, and hence gives an
opportunity for early treatment. In addition, an inflammatory component
2of diabetic complications have been recognisied as indicated by
alterations of immune cells in cornea. Furthermore it causes both
quantitative and qualitative abnormalities in tear secretion, decreased
corneal sensitivity and poor adhesion of regenerating epithelial cells.
All these imply an widespread disease of the ocular surface due to
diabetes including common diseses like dry eye, recurrent corneal
erosions to severe complications like corneal ulcerations, superficial
punctate keratopathy and persistent epithelial defects. Close monitoring
of diabetic patients as well as glycemic control is important for the
prevention of dry eye syndrome.Early diagnosis of dry eye syndrome in
diabetic patients is important for improving the ocular surface and quality
of vision(6).
We aimed to study the changes of tear film and ocular surface in
diabetics by assessing, the symptoms of dry eye using OSDI
questionnaire, tear secretion  using Schirmer’s test, tear film break‑up
time (TBUT),and the surface with the staining score by oxford scheme,
there by detecting the dry eye status in diabetics and also by comparing
the results with those of healthy controls.
3REVIEW OF LITERATURE
DRY EYE SYNDROME AND OCULAR SURFACE DISEASE:
The ocular surface is one of the most complex tissues of the body.
Stability of ocular surface enables protection and also forms an effective
refractive media for good quality of vision. Hence any condition which
affects the stability and functioning of tearfilm leads to onset of ocular
surface disease and dry eye syndrome.
DRY EYE-DEFINITION:
According to Dry Eye Workshop (DEWS) II 2017, the definition is
revised as “Dry eye is a multifactorial disease of ocular surface
characterized  by a loss of homeostasis of the tear film, and accompanied
by ocular symptoms, in which tear film instability and hyperosmolarity,
ocular surface inflammation and damage, and neurosensory abnormalities
play etiological roles.”(7)
CLASSIFICATION:
A new patient centric approach to classification have been
postulated in the DEWS II report, which helps in more understanding of
dry eye.
4Accordingly, it is divided depending on either the patient is
symptomatic or asymptomatic and then divided further into strata based
on the presenting symptoms, with corresponding clinical signs, into four
branches: asymptomatic with and without signs, also symptomatic
patients with and without signs.
Asymptomatic individuals without signs are normal, while
asymptomatic patients with signs are grouped as at risk of developing
symptoms iatrogenically (ie either following ocular procedures or other
therapeutic interventions). Symptomatic individuals with signs are further
divided into those with dry eye and those with other ocular surface
diseases (e.g., allergy, ocular cicatricial pemphigoid). Symptomatic
5individuals with no signs may have neuropathic pain or have a pre-
clinical dry eye.
Again the etiological classification proposed by DEWS II in 2017
consists of three types,
1) Aqueous deficient dry eye (ADDE)
2) Evaporative dry eye (EDE)
3) Mixed dry eye
This new classification includes a mixed dry eye group where both
aqueous deficient and evaporative dry eye can occur together and thus
require management of both in one patient.(7)
EPIDEMIOLOGY:
Age, sex and geographical location play key factors for prevalence
of dry eye disease(8). Increase in age, females have more prevalence of
dry eye and likely higher prevalence in Asians than in Caucasian
population(9,10). Other main factors that affect prevalence of dry eye
disease are diabetes and other systemic diseases, environmental factors,
contact lens wear, refractive surgery and computer system use(11).
While there appear a female preponderance for dry eye disease,
Meibomian gland dysfunction (MGD) which act as a important causative
6for dry eye disease show no female predilection and males have a slightly
higher prevalence in most age categories.
Most studies which are sign-based showed increase prevalence
with age; while, symptomatic disease was higher in younger age groups(
search south east asia studies-12)
PATHOGENESIS:
The lacrimal functional unit (LFU) consists of the secretory glands
mainly lacrimal, lids and the ocular surface comprising cornea,
conjunctiva and meibomian glands . These are linked by a neural
network, and helps in responding to external stimuli to maintain stability
of tear film and ocular surface, which is essential for a clear vision.(13)
THE LACRIMAL FUNCTIONAL UNIT
7The LFU regulates the major components of the tear film and responds to
environmental, endocrinologic, and cortical influences. Its overall
functions are
 To maintain integrity of tearfilm thus helps in lubricating, also has
antimicrobial, and nutritional roles
 Ocular surface health thereby maintaining corneal transparency
and surface stem cell population
 Proving a good quality of image being projected onto the retina
Tear film:
According to the TFOS DEWS II committee report, the tear film is
a single dynamic functional unit with different compartments. It consists
of  a lipid layer covering a complex integrated mixture of aqueous,
mucins and proteins, all of which work together to maintain tear film and
ocular surface homeostasis.(14)
8THE TEAR FILM STRUCTURE
The muco-aqueous layer forms bulk (2-6µm) of the tearfilm. It
overlies the hydrophobic  apical epithelial cells and its carbohydrate-rich
glycocalyx. This layer contains almost four major mucins, and over 1500
different proteins and peptides. Mucin, mainly secreted by the goblet cells
of conjunctiva and small amount from the surface epithelial cells provides
a smooth, hydrophilic surface permitting even distribution of the aqueous
layer.(15,16)There are numerous mucins found in tears, the major soluble
9mucin being MUC5AC and the transmembrane mucins being MUC1,
MUC4 and MUC16.
Mucins help to stabilize and even spread of tears by binding,
through their high levels of glycosylation, to water. A reduced MUC5AC
expression and alteration in glycosylation of mucins is a consistent
finding seen in dry eye among most studies.(14)
The aqueous solution is secreted by the lacrimal gland and the
accessory glands of Krause and Wolfring. It contains 98% of water with
ions of inorganic salts, glucose, urea and various biopolymers such as
enzymes, proteins and glycoproteins dissolved in it. Lysozyme ,
lactoferrin, tear specific prealbumin and secretory immunoglobulin-A are
the main constituents of protein fraction. It provides atmospheric oxygen
to the epithelium, washes the debris and noxious irritants and also has
antibacterial properties.
Changes in tear proteins levels and aminoacids from that of normal
tears have been reported in DED subjects, but these changes are yet to be
validated to aid diagnosis. If proven these can be used as possible
biomarkers of the disease.
The lipid layer is thin (0.1µ thick) and secreted by the meibomian
glands. It contains chiefly sterol esters and wax monoesters (16,17). The
10
lipid layer serves to stabilize the tear film by reducing the surface tension
and retarding evaporation.
The tear film maintains a smooth surface for optical clarity,
lubricates to facilitate eyelid blink, and offers protection against ocular
infection(19). Average tear flow is about 1.2 μm/minute(20). Blinking
serves to periodically distribute tears evenly over the ocular surface and
encourages both secretion and mechanical drainage of tears through the
lacrimal drainage system.
Corneal sensory neurons are broken down into three categories:
polymodal nociceptors, specific mechano-nociceptors and cold
thermoreceptor neurons. While polymodal nociceptors respond to
chemical, mechanical and thermal stimuli and become sensitized by
inflammation, mechano-nociceptors only respond to mechanical forces.
The most important neurons in the pathology of dry eye, researchers
suspect, are cold thermoreceptors, which discharge continuously with
normal eye surface temperature and increase or decrease the fi ring
frequency based on cooling or warming, respectively. These neurons also
seem to be sensitive to changes in osmolarity, leading the authors to
suggest that “cold-sensitive fibers contribute to the reflex control of basal
tear production and blinking.
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PATHOPHYSIOLOGY:
DED is initiated by damaging desiccation of ocular surface and
perpetuated by a vicious circle of ocular surface inflammation. The main
mechanism of DED is tear hyperosmolarity which is the hallmark of the
disease. It damages the ocular surface both directly causing pain and also
by inducing inflammatory signals.
THE VICIOUS CIRCLE OF DRY EYE DISEASE
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Two main forms of dry eye include,
i) Evaporative dry eye (EDE)-here, the tear hyperosmolarity
results from excessive evaporation from the tearfilm whereas
the lacrimal function is normal.
ii) Aqueous-deficient dry eye (ADDE)-here hyperosmolarity occurs
due to a reduced lacrimal secretion with normal rate of tear
evaporation(14)
Since tear osmolarity can raise as a result of tear evaporation in
both ADDE and EDE, it signifies all forms of DED are evaporative. EDE
is thus considered to be a hyper-evaporative state. From here, the vicious
circle seizes, leading to continous ocular surface damage, exacerbating
signs and symptoms and often changes the condition into a hybrid form
of dry eye.
In DED, hyperosmolarity  sets up a cascade of signaling events in
surface epithelial cells that leads to the release of inflammatory mediators
and proteases. These mediators, along with the hyperosmolarity itself,
cause goblet and epithelial cell loss and damage to the epithelial
glycocalyx, epithelial cell death, MMP production and also amplifies the
process of mitosis, thereby the release of extracellular DNA, which
13
activates a multicomponent inflammatory response of the ocular surface
and disturbance in mucin expression.(10)
This final results in the characteristic punctuate epitheliopathy of
DED and tear film instability, leading  to early tear film break-up which
further exacerbates and amplifies hyperosmolarity and completes the
vicious circle of events. Ultimately, this causes self-perpetuation of the
ocular surface damage.
The major causes of tear hyperosmolarity are decreased aqueous
tear flow due to failure of the lacrimal secretion and /or excessive
evaporation of the tear film. Environmental factors like low humidity,
high air flow and high temperature aids to increase evaporative loss,
which may also be caused clinically, by meibomian gland dysfunction
(MGD), which leads to an unstable tear film lipid layer.
Tear film instability can also be caused by various other factors like
xerophthalmia, ocular allergy, contact lens wear, systemic medications
causing dry eyes, topical preservative use. In blepharitis, the increase in
the normal eyelid commensals leads to alteration in the quality of eyelid
oil due to increased release of esterases and lipases than usual.
Reduction in aqueous tear flow is mainly due to impaired delivery of
lacrimal secretion into the conjunctival sac which can be physiologic due
14
to aging or drug induced, by certain antihypertensive agents,
antihistamines, and antimuscarinic agents. The most common cause of
lacrimal damage is autoimmune disorder such as Sjogren syndrome and
also in non-Sjogren syndrome dry eye (NSSDE).Inflammation causes
both destruction of the lacrimal gland and a neurosecretory block which
could be reversible. It is due to the circulating antibodies to the M3
receptor. Low androgen levels also aids inflammation.
Other factors for a reduced tear flow may be an obstructive cicatricial
conjunctival scarring or chronic ocular surface damage leading to a
reduction in corneal sensitivity and reflex tear secretion due to loss of
sensory reflex drive to the lacrimal gland. Various etiologies such as
refractive surgeries, longterm abuse of topical anaesthetics and contact
lens wear, act in part, by blocking the reflex secretion to cause dry eye.
In the initial stages of DED, the tear hyperosmolarity and epithelial
injury stimulates corneal nerve endings, leading to irritation, increased
blink rate and a compensatory, increase in the reflex tear secretion. Over
time, damage to the ocular surface leads to reduced corneal sensation and
impairment of reflex tear secretion.(21) In advanced cases of dry eye,
chronic damage to the conjunctiva results in metaplasia and
keratinization.
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CAUSES OF DRY EYE:
AQUEOUS
DEFICIENT
Sjogren’s syndrome Primary Sjogren’s
syndrome
KCS with xerostomia
Secondary Sjogren’s
syndrome
KCS with xerostomia assc.
with connective tissue
diseases such as RA, SLE,
Systemic sclerosis, GVHD
Lacrimal gland
deficiencies
Primary Age-related dry eye
Congenital alacrima
Familial dysautonomia
Secondary Lacrimal gland infiltration
-Sarcoidosis
-Lymphoma
-AIDS
-GVHD
-Lacrimal
gland ablation
-Lacrimal gland
Denervation
Lacrimal gland duct
obstruction
Trachoma
OcMMP
Erythema multiforme
Chemical and thermal burns
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Reflex hyposecretion Reflex sensory block
Contact lens wear
Diabetes
Neurotrophic keratitis
Reflex motor block
VII nerve damage
Multiple neuromatosis
Systemic drugs
EVAPORATIVE
Intrinsic(direct effect
on evaporation)
Meibomian oil deficiency
Lid aperture problems
Low blink rate
Drugs
Extrinsic (indirect
effect via changes to
ocular surface)
Vitamin A deficiency
Topical drugs/preservatives
Ocular surface diseases
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OCULAR MANIFESTATIONS:
Symptoms:
Typical complaints include burning sensation, itching, foreign
body sensation, redness, stinging, dryness, photophobia and ocular
fatigue.
Patients with aqueous tear deficiency usualy describe a diurnal
pattern with increase of symptoms over the day and difficulty in specific
environmental conditions such as low humidity areas like working in
airline cabins, change in climate, and the use of VDU terminals.(22,23)
Contrastly, increased night-time exposure, floppy eyelid syndrome, and
inflammatory conditions mostly present with more discomfort upon
awakening.
MGD causes intermittent visual blurring and usualy complain
gritty or sandy sensation. DED in diabetes and other corneal neuropathies
are asymptomatic or may have little discomfort and hence are at high risk
for keratolysis.
Signs:
Common signs of DED include conjunctival injection,
photophobia, decrease in tear meniscus height, increased tear debris, and
18
dull cornea with loss of sheen and commonly seen in the exposed
interpalpebral fissure. Paradoxical epiphora in DES is usually a result of
reflex tearing. Increased risk for external infections occurs secondary to
decreased tear turnover and damage to the surface epithelium. Instability
of the surface epithelium and disordered mucin production may cause
painful and recurrent filamentary keratitis.
Patients with SSTD have severe symptoms and more serious signs
than do NSTD patients. SSTD can present with peripheral or paracentral
sterile corneal ulcers and can be complicated with thinning and
perforation. Acute enlargement of the lacrimal gland may be seen in
SSTD. It should be differentiated from benign lymphoepithelial lesion
(Mikulicz’s disease).(24)
DIAGNOSTIC METHODOLOGY:
The diagnostic methodology includes tests to
i) Quantify patient symptoms,
ii) Visual disturbance,
iii) Tear film stability,
iv) To measure for osmolarity,
v) To quantify tear volume,
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vi) Assess ocular surface damage,
vii) Inflammation of the ocular surface and
viii) Eyelid signs (such as MGD).
Tests to quantify patient symptoms and visual disturbance:
Questionnaire’s
Symptoms are recorded through the use of  various questionnaire
instruments that are usualy self-administered by the patient or research
subject. This helps with a diagnostic score criteria to screen patients and
the need for further testing. It is also helpful to enhance standardization as
a tool in clinical research. The Ocular Surface Disease Index (OSDI) is
the most widely used questionnaire in clinical trials due to its strong
establishment in the field or the 5-Item Dry Eye Questionnaire (DEQ-5)
due to its short length and discriminative ability.(25,26)
Ocular Surface Disease Index (OSDI) Questionnaire
It is a disease specific questionnaire use to quantify the frequency
of symptoms, various environmental triggers and the impact of dry eye on
vision related quality of life The OSDI includes 12 questions divided in 3
subscales: i)symptoms associated with visual disturbance(blurred vision,
or poor vision) or ii) visual function (problems in reading, watching
20
Television, working on a computer, or driving at night) and
iii)environmental triggers.A study by  Li M, Gong et al, showed that the
DED group with 87 patients had worse OSDI total score and subscale
scores for vision-related function, compared to a other group with 71
patients without DED.(27)
Dry Eye Questionnaire (DEQ-5)
The DEQ has 4 questions related to visual disturbance, including
the frequency of visual changes, wether diurnal variation in visual
disturbance and the botherance to respondent by these variations.(28) In a
study using the DEQ, reported 10% of patients with non-Sjogren
syndrome DED and 30% of patients with Sjogren syndrome complained
of impaired vision while others reported that between 42% and 80% of
patients with primary Sjogren syndrome experienced “disturbances in
daily vision”.
Various other questionnaire available are Impact of Dry Eye on
Everyday Living (IDEEL), National Eye Institute's Visual Function
Questionnaire (NEI VFQ-25), Dry Eye-Related Quality-of-Life Score
(DEQS), Computer-Vision Symptom Scale (CVSS17), McMonnies'
Questionnaire(MQ), Ocular Comfort Index (OCI and OCI-C), Symptom
Assessment in Dry Eye (SANDE).
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Function tests:
Standard  distance and near visual acuity testing, using  Early
Treatment Diabetic Retinopathy Study (ETDRS) and Lighthouse near
vision charts, showed significant decrease in visual acuity in symptomatic
and asymptomatic OSD patients. Functional visual acuity (FVA) tests
using Landolt optotypes which tests functional vision for daily activities
is reduced in DED patients more than in controls, due to irregular ocular
surface and induced higher order aberrations.(30,31,32)
Tests for tear film stability:
1. Fluorescein Tear break-up time (TBUT)
2. Non-invasive tear breakup time (NIBUT)
3. Tear Interferometry
4. Thermography
5. Tear evaporation rate
1. Fluorescein Tear break-up time (TBUT)
Tear break-up time is measured as the time interval between the
last blink and the appearance of the first randomly distributed black spot
on the pre corneal tear film seen using the cobalt blue filter on the slit
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lamp microscope. The test is referred to as the fluorescein breakup time
(FBUT) when Sodium fluorescein dye 1mg  impregnated strips
(commonly used) is instilled to enhance visibility of the tear film The
reference value for diagnosis  of DED ranges from a cut-off time of less
than 10 seconds. (33) The European Community Study Group on
diagnostic criteria for Sjogren's Syndrome reported the sensitivity and
specificity of the test  to be 72.2% and 61.6%, respectively, in patients
with Sjogren Syndrome (34); however, mild and moderate DED patients
have varied range of FBUT values and the diagnostic value is less
certain.(35)
2. Non-invasive tear breakup time (NIBUT)
These techniques involve the observation of the reflection of
regular pattern from the tear film and measures the time for it to break-up
following the last blink.ker of definitive dry eye. A value of more than 10
seconds is normal while less than 5 seconds is marker of definite dry
eye.(36) Xeroscope, Placido-based computerisied videokeratoscopy is
used to determine NIBUT. The tear breakup pattern for tear lipid
deficiency tends to be linear on the inferior and central cornea compared
with random circular breakup pattern over areas of punctuate
epitheliopathy for aqueous tear deficiency. Automated assessment of tear
film stability is done with specific software on instruments such as the
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Keratograph (Oculus, Wetzlar, Germany), which detects and maps
locations of tear breakup over time.(37,38). The sensitivity and specificity
ranges from values of 82-84% sensitivity and 76-94% specificity
according to the specific technique used.(38-40)
3. Tearfilm interferometry
Interferometry, an non invasive technique used to assess the
stability of the tear film measures the thickness of precorneal tear film,
using  wavelength –dependent fringes; the optical path difference from
the reflection at the surface of the tear film and at the interface of the tear
film and cornea results in an interference wave, which is calculated to be
the precorneal tear film thickness(41). Normal precorneal tear thickness
varies from 2.7 to 11.0 µm. In this method, the lipid layer of the tear film
can also be evaluated. In dry eye due to lipid deficiency,lipid spreads
slowly with vertical streaking patterns compared to rapid spreading in
horizontal pattern in normal subjects. (42,43)
4. Thermography
Infrared thermography is a non-invasive method which  measures
the temperature of the ocular surface and gives an objective, quantitative
output. (44) It is based on the principle that evaporation of the tear film
leads to cooling of the ocular surface(45), and therefore measuring the
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absolute temperature and the spatial and temporal changes in temperature
during the inter-blink period, can be used as an index of tear film
stability. Literature indicates that the cooling rate of the ocular surface is
faster in individuals with DED than in normal eyes, which is responsible
for the greater of evaporation of tearfilm.(46-48). Recently, thermography
is used to differentiating various aetiologies, ADDE (with the lowest
temperatures and higher cooling rates)  and EDE (lower rates)(49).
5. Tear evaporation rate
The tear evaporation rate is used as an important  indicator of tear
film stability.(50) It is measured using different techniques such as a
vapour pressure gradient(51,52) and resistance hygrometry - which
measures the velocity of relative humidity increase within a goggle cup
placed over the eye.(53,54) Higher the evaporation rates between blinks
poorer is the tear film stability(55),and dry eye symptoms (54,56,57).It is
difficult to use it as a diagnostic tool since the evaporation rate is
dependent on humidity, ambient temperature,  and time of day at which it
is measured and it can also be affected by evaporation from the skin
surrounding the eye. There has been two-fold increase in evaporation
rate reported in patients with KCS(54).
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Tests to measure tear osmolarity:
Tear osmolarity of all clinical DED tests, is said to have the highest
correlation to disease severity (58). It is also the single best objective
marker useful in diagnosing and classifying Dry eye disease (59,60). The
osmolarity is measured using TearLab test (TearLab Corp, San Diego,
CA, USA) with 50 µl tear sample with minimal disturbance to the tear
film. It is classified as normal (302.2 ± 8.3 mOsm/L), mild-to
moderate(315.0 ± 11.4 mOsm/L) and severe (336.4 ± 22.3 mOsm/L).(58)
Tests to measure tear volume:
1. Schirmer test
2. Tear meniscometry
3. Phenol thread test
1. Schirmer test
The volume is the measured based on wetting of the whatmann
filter paper 41strip (5 x 35 mm) by hooking the folded notch at the
junction of middle one third and the temporal one third of the lower lid
margin for a period of 5 minutes. This test can be performed with
(schirmer II) and without (schirmer I) anaesthesia. Schirmer I is a well
standardized test which accounts for the measure of both basal and reflex
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secretion of tears. The test done with the patient's eye closed minimizes
the variability of results (61). Less than 10 mm of wetting without
anaesthesia or less than 6 mm of wetting with anaesthesia after 5 minutes
is considered abnormal.(62,63).
2. Tear meniscometry
The majority of tear fluid is present within the menisci (64) which
is formed by the tears lying at the junctions of the margins of both the
upper and lower eyelids and of the bulbar conjunctiva and these act as
reservoir to the precorneal tear film(65). Recently , the most appropriate
method  to study the tear volume is quantitative assessment of the tear
menisci. The tear menisci are assessed for its height(TMH), cross-
sectional area(TMA) and the meniscus curvature(TMR). The  influenctial
factors include time after a blink, measurement site along the lid margin,
time of day measured, temperature, humidity, speed of air at the locus,
and illumination (66,67). Various techniques used to assess the tear
menisci are conventional video-meniscometry, Slit-lamp mounted digital
meniscometer, Portable digital meniscometry and optical coherence
tomography (OCT) meniscometry (68,69). T OCT meniscometry
(Visante anterior segment OCT; Carl Zeiss Meditec, international,
Dublin, CA, USA), is advantageous in that it is non-invasive and  rapid
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image acquisition is rapid, but analysis of the image may be complex,
time consuming and operator-dependent (62).
3. Phenol red thread test (PRT)
This test consists of placing a thin cotton thread soaked with
phenol red, a pH sensitive dye within the outer one-third of the eyelid
margin for 15 seconds. When moistened by tears the yellow thread turns
red due to slight alkaline pH of the tears. In practice, the cut-off value of
20 mm has been accepted to differentiate aqueous deficient DED with
others.(62)
Tests to assess the ocular surface integrity:
1. Ocular surface staining
2. Impression cytology
3. In vivo confocal imaging
4. Ocular surface sensitivity
1. Ocular surface staining
Staining  helps to assess the integrity of the superficial cell layer of
the ocular surface.  The various stains used are:  sodium fluorescein, rose
bengal and lissamine green. Fluorescein sodium is the most common
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stain used in clinical practice. It stains the disrupted surface( disruption in
cell- cell tight junctions or defective glycocalyx) and not the normal
cornea due to poor penetrability of stain through the lipid layer. It is seen
better with blue-free filter.(70,71)
Rose Bengal-a derivative of fluorescein, stains ocular surface
epithelial cells that are lacking membrane associated mucin or
glycocalyx, as well as dead or degenerated cells. On instillation, it
produces stinging sensation and induces reflex tearing. It has also been
shown to be toxic to human corneal epithelial cell (72,73).
Lissamine green-a synthetic organic acid dye, stains  epithelial
cells only when the cell membrane is damaged, irrespective of the
presence of mucin. It is well tolerated and less toxic than rose Bengal
(74). A red filter (567-634 nm) is used to enhance contrast against the
sclera thereby, staining visibility.(75)
Sequential staining increases the likelihood of  ocular surface
damage. Various grading systems are present to assess the severity of
ocular surface stainig which includes the van Bijsterveld system, the
Oxford Scheme, the National Eye Institute/Industry(NEI) Workshop
guidelines, the area-density combination index, the Collaborative
Longitudinal Evaluation of Keratoconus (CLEK) schema, and the
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Sjogren's International Collaborative Clinical Alliance ocular staining
score (76-81).
Van Bijsterveld grading
It uses rose bengal staining of the conjunctiva and cornea. Staining
is evaluated on the scale of 0-3 in 3 areas-the nasal and temporal
triangular areas of conjunctiva and the cornea with a maximum score of
9. A score greater than 3 is considered abnormal.
The NEI Workshop grading
It uses fluorescein and rose-bengal for conjunctiva. A score of >3
out of 15 and >3 out of 18 is considered abnormal for cornea and
conjunctiva respectively.
Oxford scheme
The cornea and conjunctiva is graded together using fluorescein
and rose bengal or lissamine green stain. The epithelial damage is graded
using a chart with series of panels labeled A-E in order of severity
(absent,minimal,mild,moderate,severe).
The severity using oxford scheme is graded as
Grade 0-1: Normal
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Grade 2: Mild
Grade 3: Moderate
Grade >4: Severe
2. Impression cytology
Cells from the superficial 2-3 layers of the epithelium are removed
from the area of interest by applying cellulose acetate filters or biopore
membranes and then air dried and stained with periodic acid – sciff and
hematoxylin. These subsequently analyzed by subjecting to various
methods like microscopy, immunocytochemistry and molecular testing.
Squamous metaplasia and goblet cell density of the conjunctiva  are
assessed using various cytological criteria (Nelson-widely used, Tseng,
and Blade) for the diagnosis and monitoring of DED.(82-89)
3. In vivo confocal microscopy (IVCM)
It is a non-invasive technique that allows the evaluation of signs of
ocular surface damage in DED at a cellular level. It useful in assessing
decreased corneal and conjunctival epithelial cell density, conjunctival
squamous metaplasia, and corneal nerve changes like decreased sub-basal
nerve density, increased tortuosity and more.(90-95)
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4. Ocular surface sensitivity
Decreased or loss of corneal sensation leads to corneal epithelial
disorders to neurotrophic keratopathy. The techniques used are classical
Cochet-Bonnet which uses a nylon filament in varying length for
applying different intensities or non-contact air-jet
esthesiometers(CRCERT-Belmonte esthesiometer) to evaluate ocular
surface sensitivity.(96,97)
Tests for assessing the inflammation of the ocular surface:
Inflammation is an important component of the pathophysiological
mechanism of DED and  a stable indicator of DED severity.Rapid  testing
for  several inflammatory markers in DED have been developed in recent
years. The most important are Matrix Metalloproteinase (MMP-9), Th1
and Th17 subclasses of cytokines, Tear chemokines such as CXCL9, -10,
-11, and CXCR3 and others include the ocular surface immune markers.
However these tests are not disease specific and the cost of these tests
should be taken into account while advising. These tests are useful in the
aspect of research in trials targeting for newer immunosuppressive
medications for severe diseases.(98-100)
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Tests for detecting eyelid signs
These tests are to classify subtype of DED and to apply appropriate
management. The presence of blepharitis, amount of blink rate and
completeness should be noted. Lipid thickness can be observed with
interferometry and the pattern graded. Meibography performed along
with duct observation and expressibility would also be helpful (101).
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CLINICAL PROTOCOL FOR DRY EYE DIAGNOSTIC TEST
BATTERY
According to the TFOS DEWS II diagnostic methodology
subcommittee report the following test battery is recommended for
diagnosis and monitoring for DED.
DED DIAGNOSTIC TEST BATTERY
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The screening DEQ-5 or OSDI Questionnaire confirms that a
patient might have Dry eye disease. The diagnostic testing includes non-
invasive breakup time, osmolarity [measured prior to breakup time if
FBUT used] and ocular surface staining with fluorescein and lissamine
green (observing the cornea, conjunctiva and eyelid margin).
It is important to exclude conditions that forms differential
diagnosis of dry eye disease with the help of the triaging questions and
also to assess the risk factors which may indicate specific management.
Marked symptoms in the absence of clinical signs might indicate
neuropathic pain. DED is a usually a subset of OSD. Presence of only
signs in the absence of symptoms still warrants management to prevent
DED manifestations and to prepare the optical corneal surface prior to
refractive surgery or contact lens wear.
MGD features, lipid thickness/dynamics, and tear volume
assessment, and their severity inform the subtype classification of DED
as predominantly evaporative or predominantly aqueous deficient which
helps deciding the effective management of DED. In accordance with
the recommendations of the MGD Workshop (2011),
MILD MGD is indicated by a secretion grade 4-7, an expressibility
grade of 1 and an amorphous/color fringe lipid pattern.
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MODERATE MGD is indicated by meibomian gland orifice
plugging, lid margin vascularity, a secretion grade 8-12, an expressibility
grade of 2 and a meshwork or wave (flow) lipid pattern.
SEVERE MGD is indicated by lid margin meibomian gland orifice
drop-out or displacement, a secretion grade > 13, an expressibility grade
of 3 and an absent, globular or abnormal color fringe lipid pattern.
Sjogren syndrome should be suspected if the DEQ-5 score is > 12.
MANAGEMENT AND THERAPY
Management algorithms are often proposed to recommend a
sequence of treatments depending on the stage of disease, but  as the
disease often varies from patient to patient, both in severity and in
character the treatment options have to be specific for each patient. The
recommended protocol as per the DEW II management and therapy
subcommittee is given below,(102)
Recommendations for the staged management and treatment of DED:
Step 1:
 Education regarding the condition, its management, treatment and
prognosis
 Modification of local environment
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 Education regarding potential dietary modifications (including oral
essential fatty acid supplementation)
 Identification and potential modification/elimination of offending
systemic and topical medications
 Ocular lubricants of various types (if MGD is present, then
consider lipid-containing supplements)
 Lid hygiene and warm compresses of various types
Step 2:
If above options are inadequate consider:
 Non-preserved ocular lubricants to minimize preservative-induced
toxicity
 Tea tree oil treatment for Demodex (if present)
 Tear conservation
 Punctal occlusion
 Moisture chamber spectacles/goggles
 Overnight treatments (such as ointment or moisture chamber
devices)
39
 In-office, physical heating and expression of the meibomian glands
(including device-assisted therapies, such as LipiFlow)
 In-office intense pulsed light therapy for MGD
 Prescription drugs to manage DEDd
 Topical antibiotic or antibiotic/steroid combination applied to the
lid margins for anterior blepharitis (if present)
 Topical corticosteroid (limited-duration)
 Topical secretagogues
 Topical non-glucocorticoid immunomodulatory drugs (such as
cyclosporine)
 Topical LFA-1 antagonist drugs (such as lifitegrast)
 Oral macrolide or tetracycline antibiotics
Step 3:
If above options are inadequate consider:
 Oral secretagogues
 Autologous/allogeneic serum eye drops
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 Therapeutic contact lens options
 Soft bandage lenses
 Rigid scleral lenses
Step 4:
If above options are inadequate consider:
 Topical corticosteroid for longer duration
 Amniotic membrane grafts
 Surgical punctal occlusion
 Other surgical approaches (eg tarsorrhaphy, salivary gland
transplantation)
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DIABETES AND DRY EYE:
Diabetes leads to significant ocular conditions, the most important
is the retinopathy changes which is said to correlate with the duration of
diabetes and the control of the diabetes. Besides retinopathy, diabetes can
lead to other significant effects in the eye such as refractive changes,
cataracts, glaucoma, nerve palsies and dry eye. Among these dry eye is
one of the commonest complication associated with diabetes.
Pathophysiology of dry eye in diabetes
The prevalence of dry eye in diabetics has been reported to vary
between 52-54 %.(109) Several theories have been proposed for the cause
of dry eye in diabetics. The most important factors associated are:
Peripheral neuropathy secondary to hyperglycemia- Hyperglycemia
results in damage to the peripheral nerves and their signaling pathways
leading to complications like numbness, burning pain or even gangrene
and life threatening complications. In the cornea sustained hyperglycemia
along with the microvascular damage to the corneal nerves leads to
blockage of the feedback mechanism that controls the tear secretion.(103)
The lacrimal gland secretion is affected due to disruption in the
innervation of the ocular surface. The greater the degree of diabetes, there
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is increased tortuosity  of the corneal nerves which results in alteration in
the degree of corneal nerve degeneration in diabetes.(104)
Insulin insufficiency- Insulin exerts important effects on corneal and
lacrimal gland metabolism, proliferation of the epithelial cells and their
growth. A low insulin level in diabetes disturbs the biomechanical
balance of these tissues and results in dryness. (103)
Inflammation – Hyperglycemia leads to inflammatory alterations which
inturn impairs the normal tear secretion.(105)  Lacrimal gland
inflammation triggered by hyperglycemia results in lacrimal insufficiency
or aqueous deficient dry eye.
Exposure of diabetic corneas to increased glucose concentration
results in accumulation of advanced glycation end products,on the
basement membrane lamina.(106) The MMP overexpression occurs in
diabetic corneas which leads to recurrent erosions in these patients.
Diabetes and dry eye are more likely to increase the probability of cornea
ulceration than with either one condition alone.(107)
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Schematic diagram showing pathogenesis of corneal disease in
diabetes mellitus.
Symptomatology:
The most common symptoms of dry eye in diabetics are burning
and foreign body sensation. Other findings include tear film instability,
high grade conjunctival squamous metaplasia, reduction in the goblet cell
density, decreased corneal sensation and a reduced lipid layer of the tear
film.(105).
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Types of dry eye in diabetes:
Most studies suggest aqueous deficiency is the most common type
in diabetes due to the lacrimal gland insufficiency and diabetic
neuropathy blocking the neural pathways for secretion. While some
studies postulate that hyperglycemia on impairing inflammatory response
leads to bacterial invasion causing blepharitis and thereby causing
evaporative dry eye.(108)
STUDIES:
Manaviat et al studied the prevalence of dry eye and diabetic
retinopathy (DR) in type 2 diabetics with 199 subjects, among whom 108
patients (54.3%) suffered from dry eye syndrome. Although dry eye
syndrome was more common in older and female patients, this
association was not significant. But there was significant association
between dry eye syndrome and duration of diabetes (P = 0.01).Dry eye
syndrome was more frequent in diabetic patients with DR (P = 0.02). DR
was found in 140 patients (70.35%), which included 34 patients (17.1%)
with mild non proliferative DR (NPDR), 34 patients (17.1%) with
moderate NPDR, 22 patients (11.1%) with severe NPDR and 25 patients
(25.1%) with proliferative DR (PDR).They concluded that there was
significant relation between age, sex, duration of diabetes ,DR and dry
eye(109).
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Kaiserman et al compared the prevalence of keratoconjunctivitis
sicca (KCS) in a prospective cohort of 22,382 diabetic patients with that
in the general population. After age and gender adjustment, a
significantly higher percentage of diabetic patients (20.6%) received
ocular lubrication, compared with nondiabetic patients (13.8%, P < .001).
The difference was significant for all age groups and for both sexes (P <
.001). A similar significant difference was prominent between diabetic
and nondiabetic patients aged 60 to 89 years who were frequent users of
ocular lubrication. Ocular lubrication consumption increased with poorer
glycemic control (mean annual HbA1c levels). Multivariate analysis
revealed this effect to be independent of age, sex, place of birth, or place
of residence.They concluded KCS is significantly more common among
diabetic patients. Poor glycemic control correlates with increased
artificial tear use in diabetic patients. (110)
Seifart et al conducted a study on dry eye syndrome and diabetes
mellitus.92 patients with diabetes types I and II and aged from 7 to 69
years were compared with a group of normal healthy controls comparable
in number, age and sex.  The main points of comparison were subjective
complaints, objective findings on conjunctiva and cornea, break-up time
(BUT), basal secretion test, impression cytology of the conjunctiva, and
grade of diabetic retinopathy. The results show that 52.8% of all diabetic
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subjects complained of dry eye symptoms, as against 9.3% of the
controls. A BUT value lower than 10 s was found in 94.2% of the
diabetics and in only 5.8% of the controls. Basal secretion test lower than
5 mm was observed in 26% of the diabetics and in 16% of the normal
controls. Pathologic conjunctival epithelium (grade III-V after Tseng)
was found in 86% of the diabetic patients and in 6.7% of the healthy
subjects. Among the type II diabetic patients, 70% had proven dry eye
syndrome, while 57% with type I diabetes suffered from this. A positive
correlation was found between the HBA1c values and the presence of dry
eye syndrome. Impression cytology was found to give the most
distinctive and discriminating results.(111)
Goebbels et al assessed the tear secretion and tear film function in
86 insulin dependent diabetics with retinopathy and 84 non-
diabetic controls (age and sex matched).They performed
fluorophotometry of tear secretion, the Schirmer test, and impression
cytology of the conjunctival epithelium and determined the tear film
break up time and compared with the healthy control group diabetics
which showed decreased Schirmer test readings (-37%, p <0.001) and
significantly more frequent and pronounced signs of conjunctival
metaplasia.In insulin dependent diabetics, reflex tearing was
demonstrated to be significantly decreased. In contrast, unstimulated
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basal tear flow and tear film break up time were found to be normal.
However, a majority of insulin dependent diabetics showed distinct signs
of conjunctival surface disease.(112)
Nepp et al studied the correlation between the severity of Diabetic
Retinopathy and Keratoconjunctivitis Sicca. Patients with diabetic
retinopathy (DR) seldom report symptoms of ocular surface irritation, but
evaluations of dryness are pathologic.The study included 144 eyes of 72
patients. Severity of retinopathy was graded according to the Early
Treatment Diabetic Retinopathy Study. The examinations for dry eyes
included Schirmer's test, break-up time, lipid layer thickness, fluorescein
and rose bengal staining of the cornea, impression cytology, and a
questionnaire. A sicca severity score was calculated using a point system
of the results of these tests. The score of those patients with mild to
moderate retinopathy was compared to that of patients with severe to
proliferative disease. There was a significant statistical difference in the
sicca severity score between both groups, (p < 0.006. Student t test).
(113)
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JUSTIFICATION FOR THE STUDY
Few numbers of studies have been done regarding the tear film
abnormalities in diabetics and decrease in tear production has been
reported, but the overall data is inconclusive. Moreover, the ocular
surface examination is usually ignored in diabetics and much importance
is given to diabetic retinopathy in routine practice. Hence the present
study is undertaken to evaluate the amount of tear production, the
stability of the tear film and the condition of the ocular surface in diabetic
individuals in order to detect possible ocular surface disease and its
association with diabetic retinopathy.
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AIMS AND OBJECTIVES
1) To evaluate the dry eye status in patients with  type II diabetes.
2) To study the association between dry eyes and retinopathy in
patients with type II diabetes.
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MATERIALS AND METHODS
MATERIALS AND METHODS
 This was a hospital-based cross-sectional study which included
patients with Type 2 Diabetes Mellitus who were attending the
Ophthalmology Department in PSG Institute of Medical Sciences
and Research, Coimbatore.
 The study was done spanning over a period of 18 months from
January 2016 to June 2017.
 A convenient sample of 100 patients with type II diabetes and 100
matched controls were chosen
Inclusion criteria:
 Type II diabetic patients who attended the ophthalmology
OPD in PSG Hospitals.
 Age and Sex matched non diabetic controls have been
recruited from healthy volunteers.
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Exclusion criteria:
 Patients on systemic medications such as antihistamines,
tricyclic antidepressants, oral contraceptives and other
medications which are known to cause dry eye.
 Contact lens users
 Patients who have undergone ocular surgery
(LASIK/intraocular).
 Patients having local or systemic conditions other than
diabetes mellitus known to cause dry eye.
 Smokers
METHODOLOGY:
After clearance from  the Institutional Ethical Committee in
accordance with the guidelines of the Declaration of Helsinki and taking
informed consent, detailed history of each patient was obtained regarding
the age, sex, occupation and presenting symptoms, duration, progression
and associated conditions. Detailed history regarding diabetes such as
type, duration, type of treatment, HbA1c values, FBS and PPBS levels
were recorded.
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Ocular surface disease index (OSDI) questionnaire was used to
score the dry eye symptoms. It consisted of 12 questions which were
grouped under 3 subsets: visual disturbance, visual function and
environmental triggers. Score of maximum 4 was given for each question
based on the severity of the symptom and subtotal for each subset
calculated. The subtotal scores were added to get the total score and the
OSDI was calculated using the formula OSDI = (total score) x 25 the
whole divided by the number of questions answered. Using the OSDI
score the patients were categorized as normal(0-12), mild dry eye(13-22),
moderate dry eye(23-32) and severe dry eye(33-100).
Ocular examination included recording best corrected visual acuity
and detailed anterior segment examination under slit lamp. The dry eye
was detected by measuring tear film breakup time (TBUT), ocular
surface dye staining pattern with fluorescein and schirmer's test.
TBUT test was performed by staining the tear film using a
fluorescein impregnated strip without using topical anesthesia and asking
the subjects to blink three times and then cease blinking until instructed.
The tear film was observed using a slit lamp with blue cobalt filter. The
time interval between the last blink and the appearance of the first
random corneal dry spot in the tear film was measured. A value <10
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seconds was considered abnormal. TBUT results graded as >10 secs –
normal, 6-10 secs – mild to moderate, and <6 secs – severe.
Ocular surface staining was evaluated by staining the cornea with
fluorescein. The staining area was graded using the Oxford Scheme on a
numerical scale of 0–5 for the entire ocular surface based on comparison
to the standard panel, with 0 representing equal to or less than panel A, 1
representing equal to or less than panel B but greater than panel A, 2
representing equal to or less than panel C but greater than panel B, 3
representing equal to or less than panel D but greater than panel D, 4
representing equal to less than panel E but greater than panel C, 5
representing greater than panel E. The severity was graded based on the
score as 0-1 as normal, 2 as mild, 3- moderate and >4 as severe.
Schirmer test was performed without topical anesthesia using
standardized Whatman filter paper 41. The strips were placed in the lower
fornix away from the cornea and left in place for 5 min with the patient
opened eyes. The wetting distance was measured in millimeters, and a
reading <10 mm was considered abnormal.
Retinal status evaluation done by slit lamp bimicroscopy using 90D
lens after puppilary dilation. Diabetic retinopathy was graded according
to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria.
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Statistical analysis
Statistical analysis was performed using SPSS version 19. The
baseline characteristics of patients were presented as mean±standard
deviation and n (%). Data on the patient’s clinical characteristics were
compared using One-way Analysis of Variance (ANOVA) as well as an
independent sample Student’s t-test and Chi-square test was used to see
the comparison between the proportions. All tests for statistical
significance were two-tailed, and performed assuming a Type I error
probability of <0.05.
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OCCURRENCE OF DRY EYE IN DIABETICS
Dry eye
Total
Chi-
square
statistics
No Yes
Diabetic With
No Retinopathy
N 31 16 47
19.069**
(p=.000)
% 66.0% 34.0% 100.0%
Diabetic with
Retinopathy
N 12 41 53
% 22.6% 77.4% 100.0%
Total
N 43 57 100
% 43.0% 57.0% 100.0%
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Among 100 patients with diabetes, 57 patients were diagnosed to have
dry eye. Out of 47 patients without retinopathy, 16 patients (34%) were
found to have dry eye and out of 53 patients with retinopathy, 41 patients
(77.4%) had dry eye.
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AGE DISTRIBUTION OF DRY EYE IN DIABETICS
Dry Eye
Total
No Yes
Age
30-40 years
N 4 2 6
% 66.67% 33.33 100.0%
41-50 years
N 11 16 27
% 40.74% 59.26% 100.0%
51-60 years
N 14 19 33
% 42.42% 57.58% 100.0%
Above 60
years
N 14 20 34
% 41.17% 58.83% 100.0%
Total
N 43 57 100
% 43.0% 57.0% 100.0%
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The mean age of diabetics without dry eye was 54.77 ± 9.82 years and the
mean age of diabetics with dry eye was 56.49±9.32 years. As the age
increased, the occurrence of dry eye also increased significantly. Out of
34 patients in the age group more than 60 years, 20 patients (58.83%)
had dry eye.
0
5
10
15
20
30-40 years
NU
MB
ER
 OF
 PA
TIE
NT
S
41-50 years 51-60 years >60 years
AGE GROUP IN DIABETICS
DRY EYE
NO
YES
59
SEX DISTRIBUTION OF DRY EYE IN DIABETICS
Dry Eye
Total
No Yes
Gender
MALE
N 24 31 55
% 43.63% 56.37% 100.0%
FEMALE
N 19 26 45
% 42.22% 57.78% 100.0%
Total
N 43 57 100
% 43.0% 57.0% 100%
Of the 100 consecutive patients included in the study, 55 were male and
45 were female. Among 55 male patients, 31 patients(56.37%) had dry
eye and among 45 females patients, 26 patients(57.78%) had dry eye
symptoms.
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AGE DISTRIBUTION AMONG DIABETIC PATIENTS
Diabetic
Retinopathy Total
No Yes
Age in years
30-40 years
N 5 1 6
% 83.3% 16.7% 100.0%
41-50 years
N 14 13 27
% 51.9% 48.1% 100.0%
51-60 years
N 16 17 33
% 48.5% 51.5% 100.0%
Above 60
years
N 12 22 34
% 35.3% 64.7% 100.0%
Total
N 47 53 100
% 47.0% 53.0% 100.0%
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Mean age in diabetic patients without retinopathy was 53.72 ± 9.88 years,
while in diabetic patients  with retinopathy was 57.55 ± 8.93 years. With
increasing age, the number of patients with diabetic retinopathy also
increased significantly. Out of 34 patients in the age group more than 60
years, 24 patients (64.7%) had retinopathy of some degree.
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SEX DISTRIBUTION AMONG DIABETIC PATIENTS:
Diabetic Retinopathy
Total
No Yes
Sex
Male
N 26 29 55
% 47.3% 52.7% 100.0%
Female
N 21 24 45
% 46.7% 53.3% 100.0%
Total
N 47 53 100
% 47.0% 53.0% 100.0%
Of the 100 consecutive patients included in the study, 55 were male and
45 were female. Among 55 male patients, 26 patients(52.7%) had
diabetic retinopathy and among 45 female patients, 24 patients(53.3%)
had  diabetic retinopathy.
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DRY EYE AMONG DIABETICS BASED ON OSDI:
OSDI GRADING NO. OF PATIENTS
Normal 49
Mild 20
Moderate 20
Severe 11
Total 100
Based on OSDI Questionnaire, 51% of patients had symptomatic dry eye.
20% of patients had mild dry eye, 20% had moderate dry eye and 11%
had severe dry eye symptoms.
20% 49%
20%
11%
OSDI Grading
Normal
Mild
Moderate
Severe
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DRY EYE AMONG DIABETICS USING TBUT:
TBUT GRADING NO. OF PATIENTS
NORMAL 58
MILD-
MODERATE
38
SEVERE 4
TOTAL 100
T BUT was abnormal in 42% of diabetics. Among them 38% had mild-
moderate values while severe dry eye was found in 4% of patients.
58%
38%
4%
TBUT GRADING
NORMAL
MILD-MODERATE
SEVERE
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ASSOCIATION OF DRY EYE WITH DURATION OF DIABETES:
Dry eye
Total
Chi-
square
statisticsNo Yes
Duration
of
diabetes
1-5 years
N 29 20 49
12.847**
(p=.005)
% 59.2% 40.8% 100.0%
6-10 years
N 9 22 31
% 29.0% 71.0% 100.0%
11-20 years
N 3 14 17
% 17.6% 82.4% 100.0%
>20 years
N 2 1 3
% 66.7% 33.3% 100.0%
Total
N 43 57 100
% 43.0% 57.0% 100.0%
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Significant Association between diabetic duration and Dry eye was
observed (p < 0.05), Occurrence of dry eyes was 71% in diabetics with
duration more than 6 years and 82.4 % in diabetes with duration more
than 11 years.
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ASSOCIATION OF DRY EYE WITH HbA1c LEVELS IN
DIABETICS:
Dry eye N Mean SD t-value
HbA1C
No 43 8.55 2.31 1.808
(p=.074)Yes 57 9.39 2.29
The mean HbA1c values of diabetics with and without dry eye were
8.85±2.41 and 9.20±2.27 respectively. There was no significant
association between the HbA1c levels and the dry eye status in diabetics
(p-value = 0.074).
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STAGING OF RETINOPATHY IN PATIENTS WITH TYPE II
DIABETES:
STAGING No. of patients
No DR 47
Mild NPDR 14
Moderate NPDR 16
Severe NPDR 12
PDR 11
Total 100
In our study,  47% of patients had no signs of retinopathy, 14 % had mild
non proliferative diabetic retinopathy (NPDR), 16% had moderate NPDR,
12% had Severe NPDR and 11% had Proliferative diabetic retinopathy
(PDR).
47%
14%
16%
12%
11%
Staging of Diabetic retinopathy
No DR
Mild NPDR
Moderate NPDR
Severe NPDR
PDR
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CLINICAL CHARACTERSTICS OF STUDY POPULATION:
Characteristic
Study group
Control
group
(n=100)
Diabetic with no
retinopathy (n=47)
Diabetic with
Retinopathy
(n=53)
Mean SD Mean SD Mean SD
Age (yr) 54.7 10.23 53.72 9.88 57.55 8.93
DM_duration
(yr)* - - 4.86 5.23 8.79 5.53
HbA1C(%) - - 8.85 2.41 9.20 2.27
Schirmer (mm)* 24.15 5.15 11.67 4.41 10.04 3.42
TBUT(sec)* 14.65 3.68 13.94 4.66 11.44 4.23
OSDI* 6.98 6.52 8.04 8.26 21.37 12.16
DM:Diabetes mellitus, TBUT:Tearfilm breakup time, OSDI:Ocular
surface disease index
*  p-value < 0.05
The mean age of subjects in the control group was 54.7± 10.23
years, in diabetics without retinopathy was 53.72±9.88 years and in
diabetics with retinopathy was 57.55±8.93 years. The mean duration of
diabetes in patients without retinopathy was 4.86±5.23 years while the
duration of diabetes in patients with retinopathy was 8.79±5.53 years.
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The mean HbA1c values of diabetics with and without retinopathy
were 8.85±2.41% and 9.20±2.27 % respectively. There was no
siginificant association between the HbA1c levels and the dry eye status
in diabetics (p-value = 0.074).
The mean schirmer test value in control group was 24.15±5.15
mm, in diabetics without retinopathy was 11.67±4.41 mm and in
diabetics with retinopathy was 10.04±3.42 mm.
The mean TBUT value in control, diabetics without retinopathy
and diabetics with retinopathy were 14.65±3.68 secs, 13.94 ± 4.66 secs
and 11.44±4.23 secs respectively. There was significant difference in the
TBUT values between all the three groups with the lower values in the
diabetic retinopathy group.
The mean OSDI score in control group was 6.98±6.52, in diabetics
without retinopathy was 8.04±8.26 and the diabetics with retinopathy was
21.31±12.16. Significant difference was noted between the control and
diabetics with retinopathy group (p-value=0.00) while no significant
difference was noted between the control group and the diabetics without
retinopathy.
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TABLE SHOWING ASSOCIATION BETWEEN DRY EYE AND
SEVERITY OF DIABETIC RETINOPATHY:
Diabetic
retinopathy(DR)
Ocular surface staining
Total
Chi-
square
value
NORMAL MILD MOD SEVERE
78.730**
(p= .000)
NO DR
N 36 8 2 1 47
% 76.60 17.02 4.26 2.13 100
MILD
NPDR
N 9 2 3 0 14
% 64.29 14.29 21.43 0 100
MOD
NPDR
N 4 5 6 1 16
% 25.00 31.25 37.50 6.25 100
SEVERE
NPDR
N 0 5 4 3 12
% 0.00 41.67 33.33 25.00 100
PDR
N 0 0 5 6 11
% 0.00 0.00 45.45 54.55 100
Total N 49 20 20 11 200
There was significant association found between dry eye status and
diabetic retinopathy (p<0.01). More cases in Diabetic Retinopathy group
reported with moderate and severe dry eye. The percentage of patients
having dry eye among patients with no diabetic retinopathy was 23.41%
as against and 35.72% in mild NPDR, 75% in moderate NPDR, 100% in
severe NPDR and PDR patients respectively. All the patients with severe
NPDR  and PDR had some form of dry eye.
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DISCUSSION
Our study shows that abnormal OSDI scores, TBUT, Schirmer test
and ocular surface staining were noted in diabetic patients compared to
controls. These observations indicate that dry eye is a significant factor
responsible for ocular surface disease in diabetics. Moreover, a positive
association was noted between dry eye status and severity of diabetic
retinopathy.
In our study the prevalence of dry eye in diabetics was 57%. In
particular, diabetics with retinopathy, had higher prevalence(77.4%) of
dry eye than diabetics without retinopathy .Similar to our study Seifart et
al found 52.8% of diabetics had dry eye symptoms  among 92 patients
included their study.(113) Adequate glycemic control  could prevent dry
eye disease as well as retinopathy progression in diabetics. However
their study included both type I and type II diabetics. High prevalence
could be attributed to reduced tear secretion in DM patients caused by
autonomic dysfunction in these patients. The tropical and dry climate in
our region would be an added factor for the increased prevalence of dry
eye in our study.
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In our study, the mean age of diabetics with dry eye was
56.49±9.32 years. Dry eye was more prevalent in patients aged over 50
years showing a significant association between the age and dry eye.
Of the 100 consecutive patients included in the study, 55 were male
and 45 were female. Among 55 male patients, 31 patients(56.37%) had
dry eye and among 45 females patients, 26 patients(57.78%) had  dry eye
symptoms. There was a slightly higher preponderance among female
patients which could be attributed to thinner lipid layer of the tearfilm of
the females.
We also found a significant association between dry eye disease
and the duration of diabetes in our study. Longer the duration of diabetes,
higher was the prevalence of dry eye disease. About 71% of patients with
duration of diabetes more than 6years had dry eye symptoms. 82.5 % of
diabetics with more than 11 years of diabetes had dry eye symptoms.
In the present study, we found no significant association between
the HbA1c levels and dry eye(p=0.074).This was in contrast to previous
studies by Seifart et al who found a positive correlation between the
HBA1c values and the presence of dry eye syndrome and Kaiserman et
al, also found a higher use of artificial tears in diabetic subjects with a
higher HbA1c levels.(111,110) Our observations are consistent with that
of Fuerst et al who assessed the relationship between tear osmolarity and
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dry eye symptoms in 50 diabetics and found no correlation in HbA1c
levels with the dry eye disease.(114) This could be explained  by the fact
HbA1c levels reflect only the average blood glucose level over the
previous 3 months. Hence, HbA1c levels may not necessarily correlate
with dry eye and ocular surface abnormalities which occurs over years of
poorly controlled diabetes.
Based on the OSDI symptom scores, among the 100 diabetic
patients 51% of patients had symptomatic dry eye. Among them, mild dry
eye was noted in 20% of patients, moderate dry eye in 20% of patients
and 11% had severe dry eye. The frequency of dry eye symptoms in our
study matched to that of Manaviat et al, who found that 54% of 199
diabetic subjects had dry eye symptoms.(109) Our study showed
significant difference in the OSDI scores between the diabetics with
retinopathy and the non diabetic group while no significant difference
between the diabetics without retinopathy and the controls.
In our study, significant differences in TBUT and schirmer test was
observed (p<0.05) among allthe study group with lower TBUT in patients
with diabetic retinopathy. Abnormal TBUT value (<10 secs) was seen in
40% of the diabetic group. Schirmer test was abnormal (<10mm / 5min)
in 54% of diabetic subjects. A study by Dogru et al also  noted
significantly reduced TBUT and Schirmer test values in diabetic patients
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with peripheral neuropathy and poor metabolic control.(115) Presence of
autonomic dysfunction, abnormalities  in the tear film dynamics, decrease
in corneal sensation , along with microvascular damage to lacrimal gland
contribute to the increased prevalence of dry eye in diabetics.
Of the 100 patients with type 2 diabetes included in our study,
diabetic retinopathy was detected in 53%. The results are consistent with
the Wisconsin Epidemiological Study for Diabetic Retinopathy
conducted in the USA which studied 1313 subjects and reported 50.3%
had DR but this study included the type 1 diabetics too.(116).Ruta LM et
al reviewed various epidemiological studies and reported the prevalence
varied from as low as 10% to as high as 61% in known diabetic  persons
and from 1.5 to 31% in newly diagnosed persons. The median prevalence
of any diabetic retinopathy in known diabetes was 27.9% (22-37%) with
higher prevalence in developing countries.(117)
In our study, the mean age in diabetic patients without retinopathy
was 53.72 ± 9.88 years, while in diabetic patients with retinopathy was
57.55 ± 8.93 years. With increasing age, the number of patients with
diabetic retinopathy also increased significantly. 64.7 % patients aged
above 60 years had some degree of retinopathy.
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The male:female ratio was about 55:45 in the diabetic group. The
percentage of females (53.3%) with diabetic retinopathy was slightly
higher compared to males(52.7%).
We compared the dry eye status with the staging of retinopathy in
diabetics and observed a significant association between dry eye and the
severity of diabetic retinopathy (p<0.05). The proportion of patients with
dry eye was significantly higher in patients with advancing grades of
retinopathy. Several other studies have also reported a positive correlation
between diabetic retinopathy and dry eye. Nepp et al found a significant
statistical difference in the sicca severity score between patients with mild
to moderate diabetic retinopathy and severe to proliferative disease.(113)
Ozdemir et al and Yu L.et al reported a declined tear film function  in the
diabetics with PDR than in those with NPDR.(118,119)
Several mechanisms can account for the observed results in our
study. Oxidative stress and inflammation are common underlying factors
in the pathogenesis of dry eye as well as diabetic retinopathy. Progressive
damage to corneal nerve fibres as a result of diabetic neuropathy can lead
to impaired corneal sensation and dry eye which correlates with the
severity of diabetic retinopathy.
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CONCLUSION
 Patients with type II diabetes have higher prevalence of dry eye
when compared to their age matched controls in our study.
 Evaluation of diabetic patients using the OSDI questionnaire can
be helpful in identifying dry eye in early stages.
 Significant association was noted between dry eye disease and the
duration of diabetes.
 No correlation was found between HbA1c levels and dry eye status
in patients with diabetes.
 Significant reduction in TBUT and Schirmer test was found in
diabetic patients, especially those with retinopathy.
 A positive association was observed between severity of
retinopathy and dry eye.
Patients with advanced diabetic retinopathy are at increased risk of
developing ocular surface complications. Hence our study insists that
clinical evaluation of dry eye should be an integral part of ocular
examination in diabetic patients.
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LIMITATIONS
 Cross sectional design of the study
 Limited sample size
 Lack of more objective tests like conjuctival impression cytology
and tear osmolarity measurement are  limitations of our study.
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CASE PROFORMA
 NAME
 AGE
 SEX
 IP/OP NUMBER
 ADDRESS
 PRESENTING COMPLAINTS
HISTORY OF PRESENTING ILLNESS
 DURATION OF DIABETES
 SPECTACLE WEAR (DURATION, FOR NEAR OR DISTANT
VISION)
PAST HISTORY
 OTHER OCULAR DISEASES
 OTHER CO-EXISTING SYSTEMATIC CO MORBIDITIES
OSDI QUESTIONNAIRE
TBUT SCALE
OCULAR SURFACE STAINING GRADE
SCHIRMER TEST GRADING
101
OPHTHALMIC EXAMINATION
 VISUAL ACUITY(INCLUDING PIN HOLE)
 HEAD POSTURE
 FACIAL SYMMETRY
 EOM
RIGHT EYE LEFT EYE
 LIDS AND ADNEXA
 CONJUNCTIVA
 CORNEA
 SCLERA
 ANTERIOR CHAMBER
 IRIS
 PUPIL
 LENS
 VITREOUS
 IOP
 FUNDUS
 DETAILS OF INVESTIGATION DONE: HBA1C LEVELS
102
MASTER CHART
S.No OP /IP No AGE SEX DMDuration OSDI
Schirmer TBUT KES
DR HbA1C
RE LE RE LE RE LE
1 O17042831 55 M 1 5.5 13 8 13.11 13.71 1 0 0 6.9
2 O17053371 55 F 3 3.1 8 10 6.63 6.25 0 1 0 7.6
3 O17034527 54 F 1 9 0 3 6.02 6.02 1 0 0 7.9
4 O17040600 43 F 1 0 2 2 5 15.67 0 0 0 11.3
5 O12004626 43 F 6 7.5 13 9 10.65 16.65 0 1 0 6.8
6 O07013550 52 M 11 12.5 13 12 10.72 18.56 2 2 0 10.6
7 O17029213 45 F 1 20 12 11 8.52 10.72 2 2 0 7.3
8 O04010153 48 M 1 2.3 10 13 10 12.52 1 0 0 10.9
9 O17024311 53 M 1 11.36 9 10 15.76 14.69 0 0 0 11.3
10 O08021872 56 F 3 12.27 11 8 10 7.8 2 2 0 7.8
11 O05021945 62 M 20 10 9 7 12.62 13.46 0 1 1 7
12 O08039184 76 M 1 7.14 10 9 15.29 10.06 0 0 0 15.2
13 O17004644 75 F 5 8.3 9 8 13 12 1 0 2 7.7
14 O17021152 55 M 2 0 11 15 15.39 16.99 0 1 0 6.9
15 O17020226 60 M 10 41.7 11 8 6.8 8.07 4 4 0 15.6
16 O17016289 68 M 5 22.7 8 6 11.62 13.68 3 3 2 11
17 O13004530 48 M 1 11.36 0 0 6 8.23 1 1 0 10.4
18 O17006960 52 F 5 5.5 14 8 13.53 14.58 0 0 0 9.3
19 O16088307 42 M 5 34.09 8 8 10 6 5 5 3 14
20 O17004943 55 F 9 16.67 9 9 8.42 12.43 2 2 3 11.2
21 O15070604 59 F 1 13.89 9 5 4 5.8 2 2 0 7.6
22 O15079150 50 M 10 50 7 8 8 12 4 5 4 11.3
23 O16066297 65 F 20 42.85 9 10 8 9.5 4 4 3 8.6
24 O16051099 60 F 5 0 10 13 20 10 0 1 0 7.8
25 O16064404 55 F 1 0 12 11 8 15 0 0 0 7.56
26 O16067449 65 F 12 25 10 9 10 11 3 3 4 13
103
27 O16066843 65 M 15 22.22 11 10 10 6 3 3 0 8.9
28 O14068958 66 M 20 7.5 10 11 10 18 1 0 0 8.8
29 O97001385 57 F 15 4.5 9 10 12.18 17.16 0 0 1 7.4
30 O16073366 40 M 1 27.5 11 13 12 13 3 3 0 5.5
31 O16021635 51 F 10 27.5 9 8 20.67 28.23 3 3 1 7.8
32 O17048689 49 M 3 10 16 11 24 25.08 1 0 0 8.5
33 O02040942 57 F 6 18.75 14 12 7 5 2 2 0 10.6
34 O17027395 45 M 1.5 8.33 12 9 19.06 10.05 0 1 0 9
35 O98019981 44 F 6 15 11 9 25.38 22.36 2 2 0 11
36 O12007866 59 M 25 9 8 9 17.86 20.62 0 1 2 13.7
37 O16009726 49 M 10 6.25 7 6 6.07 8.84 0 0 0 9
38 O17053397 43 M 1 0 12 15 15.8 16 1 1 0 9.8
39 O13078315 77 M 1 13.89 14 12 13 15.25 2 2 0 6.7
40 O17056102 49 F 15 13.89 9 13 7.22 7.45 2 2 3 5.6
41 O17066003 40 M 4 12.5 10 8 10 13 2 2 3 12.9
42 O13090437 50 M 5 15 9 10 10.94 13.62 2 2 2 7.8
43 O16054656 64 M 2 22.7 9 8 12.16 14.42 3 3 3 9.7
44 O17025189 52 F 7 16.67 12 9 8 11 2 2 3 7.6
45 O17064327 46 F 1 7.14 15 12 15.29 13.08 0 0 0 13
46 O16050783 45 F 1 11.36 14 13 15.53 14.97 0 0 0 12.3
47 O16061638 67 M 12 12.5 16 14 10.76 18.54 2 2 0 7.3
48 O14012504 67 F 7 7.5 12 10 10.64 15.56 1 0 0 6.5
49 O17069821 62 M 6 27.5 7 8 10.45 9.8 3 3 2 7.7
50 O17035821 57 M 5 10 8 10 13.44 12.56 1 1 1 8.7
51 O17066524 62 M 8 25 11 8 10.67 8.02 3 3 2 8.9
52 O08077379 51 M 6 6.8 15 12 15.65 16.45 0 0 0 7.3
53 O17032118 61 F 7 18.75 10 11 7.8 5.2 2 2 2 10.2
54 O17031224 51 M 6 34.09 7 8 10.5 7.08 4 5 4 8.8
55 O00024886 78 M 15 32.5 8 9 6.07 10.2 4 4 4 10.7
56 O06020524 67 F 10 5.6 16 13 17.62 18.32 0 0 0 7.6
57 O16029085 60 F 6 10.2 10 9 20.76 24.32 1 1 1 6.7
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58 O13071510 40 F 3 0 12 12 21.9 17.54 0 0 0 6.3
59 O12016723 50 M 5 25.2 11 7 13.32 12.02 3 3 3 8.2
60 O17056688 64 M 10 29.54 9 11 10 7.56 3 3 4 8.9
61 O14033474 62 M 8 0 13 14 12.88 17.89 1 1 0 7
62 O17056075 61 M 7 7.5 15 12 10.76 12.45 0 0 0 8
63 O05019509 53 M 8 31.18 8 11 6.07 8.38 3 3 4 12.1
64 O13022843 44 M 5 0 11 13 18.32 12.88 0 0 2 6
65 O15029314 61 F 6 8.33 10 12 20 22 0 1 1 7.8
66 O16004903 71 F 11 27.78 11 12 7.33 8.34 3 3 2 8.9
67 O17056576 52 F 2 3.1 9 12 6.66 6.52 0 0 1 8.2
68 O12058548 58 M 4 22.7 12 11 11.26 16.38 3 3 2 9.7
69 O06003668 52 F 4 11.11 11 12 13 11.9 0 0 1 9.6
70 O08068133 50 F 6 22.7 10 12 16.12 16.38 3 3 2 9.6
71 O17030556 40 F 1 0 12 14 15.87 19.72 1 0 0 7.1
72 O09046532 57 M 12 41.7 10 11 10 4 5 5 4 9.4
73 O17038744 50 F 6 25 11 13 8.07 6.8 3 3 4 13.2
74 O17030193 69 M 6 20.45 9 12 8.23 7.66 2 2 2 7.7
75 O17030153 65 M 2 5.5 12 14 15.33 14.69 0 0 0 5.4
76 O17055247 56 M 6 22.9 8 11 6.07 8.32 3 3 3 7.9
77 O17030466 48 M 4 0 17 18 18.89 17.53 0 1 0 9.8
78 O17026180 65 M 5 8.33 15 11 19.07 16.05 0 0 0 8.9
79 O11066763 63 F 5 0 7 11 18 20 1 0 1 8.3
80 O17030288 44 F 2 0 11 16 20 21 0 0 0 10.7
81 O14069491 53 F 8 3.1 8 10 16.66 12.64 0 1 0 9.7
82 O13071510 40 F 1 0 10 12 22 21.8 0 0 0 6
83 O17029477 67 M 13 46.8 11 8 7.73 9.5 5 4 4 12.3
84 O17029761 45 F 4 12.5 13 12 10 13 2 2 3 9.1
85 O17028456 45 M 5 5.5 11 12 15.43 18.45 1 0 2 6.5
86 O17028524 51 M 6 34.09 10 11 10 6.08 4 5 2 15.8
87 O17028330 66 M 3 5.5 12 9 13.88 15.84 0 1 1 7.6
88 O16086025 49 F 20 39.2 11 12 8.2 7.35 5 5 3 9.1
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89 O02044819 63 M 25 10 12 11 12.64 18.36 0 0 0 7
90 O03007536 72 M 14 25 10 13 10 11.2 3 3 1 8.2
91 O11084068 66 M 21 15 12 11 12.09 18 2 2 2 5.8
92 O03033812 68 F 5 15 12 10 11.7 9.4 2 2 1 6.6
93 O17065252 60 F 6 18.75 12 12 7.6 5.9 2 2 1 7
94 O17036114 47 F 7 42.85 11 10 4.7 8.5 4 5 4 10.6
95 O16026308 69 M 12 25 12 15 10 11 3 3 4 7.9
96 O17052125 52 M 8 22.22 11 10 10 11 3 3 1 11
97 O08014677 37 M 1 0 12 14 18.4 22.75 1 0 0 6
98 O17035302 47 F 4 31.81 9 12 10 9.5 3 3 3 9.1
99 O17035144 60 M 5 0 13 8 15.56 16.48 1 0 0 13.5
100 O13046441 61 F 20 12.5 10 11 10.3 11.8 2 2 2 7.4
106
S.No OP /IP No AGE SEX OSDI
Schirmer TBUT KES
RE LE RE LE RE LE
101 O16068246 57 M 16.67 24 30 11.43 12.68 0 0
102 O08019314 40 F 6.8 25 30 8.02 10.04 0 0
103 O17027888 60 F 15.63 30 30 12.68 13.42 0 0
104 O17027875 45 M 9.1 25 30 14.52 9.92 0 0
105 O14055883 43 F 25 30 20 20.05 18.26 0 0
106 O17047525 37 M 0 35 35 26.08 21.07 0 0
107 O17044023 53 F 0 10 15 18.35 15.65 0 0
108 O17046507 45 F 7.5 25 30 30 31 0 0
109 O17027967 40 M 13.64 15 10 20.4 17.86 0 0
110 O17021151 34 M 9.1 35 35 14 13.8 0 0
111 O17021132 50 M 6.8 25 20 12.8 11.82 0 0
112 O17021131 38 M 2.3 20 15 13 20 0 0
113 O160O2609 44 M 15.9 30 30 15.4 14.86 0 0
114 O17038167 45 M 2.27 25 30 15.26 18.36 0 0
115 O17055115 50 F 7.5 25 23 21.8 18.12 0 0
116 O17038460 48 M 7.5 25 30 22 20 0 0
117 O17038093 70 F 6.25 24 21 12.68 13.43 0 0
118 O17007348 61 F 15.63 21 19 21.8 23 0 0
119 O05017545 40 F 0 25 27 23 21.22 0 0
120 O17008208 52 M 6.8 25 20 13.9 14.53 0 0
121 O17069256 75 F 12.5 18 19 12.68 14.23 0 0
122 O17055113 60 F 5.5 22 18 18.64 16.72 0 0
123 O97025965 74 M 16.67 18 23 15.67 13.45 0 0
124 O97025966 74 F 11.11 17 25 23.8 24.55 0 0
125 O96005542 43 F 0 22 27 20.5 23.3 0 0
126 O17057173 60 M 0 30 30 21.43 19.81 0 0
127 O12050495 61 F 15.63 30 30 17.89 18.91 0 0
128 O14024350 58 F 5.5 25 23 18 17.53 0 0
129 O17069160 52 F 0 12 15 18.55 16.78 0 0
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130 O11083082 70 M 14.28 15 18 17.84 19.2 0 0
131 O17038390 60 M 5.5 23 32 21 22.92 0 0
132 O17014979 65 F 11.11 28 26 13.67 14.86 0 0
133 O17050683 50 F 0 30 30 15.67 17.8 0 0
134 O17025189 52 F 0 24 28 12.56 13.78 0 0
135 O17064893 53 F 6.8 24 25 12.44 16.32 0 0
136 O17068894 75 F 12.5 14 18 12.68 11.72 0 0
137 O07017172 52 F 5.5 26 20 21.88 24.56 0 0
138 O17021119 48 M 5.5 25 30 19.8 16.76 0 0
139 O17021126 44 M 0 30 30 22.6 23.54 0 0
140 O17021117 49 M 6.8 25 20 21.58 18.12 0 0
141 O17021129 47 M 9.1 25 30 15.23 19.29 0 0
142 O17021134 45 M 7.5 25 30 20 21 0 0
143 O1703588 56 M 16.67 24 30 14.31 16.82 0 0
144 O17069951 59 M 16.67 28 32 13.14 12.86 0 0
145 O17038849 45 F 7.5 26 25 23 22.65 0 0
146 O17069833 62 M 15.63 30 30 16.82 14.32 0 0
147 O16001030 46 F 7.5 23 25 22 24.8 0 0
148 O17060133 67 F 12.5 17 19 15.9 17.5 0 0
149 O13034426 62 F 11.11 25 28 14.88 16.79 0 0
150 O17057628 40 F 0 30 30 16.8 18.54 0 0
151 O1502620 48 M 0 25 25 20.16 21.9 0 0
152 O17060137 57 M 0 23 21 15.8 16.9 0 0
153 O14023142 59 F 7.5 30 30 22.5 21.8 0 0
154 O16064196 65 M 5.5 20 18 15.56 15.43 0 0
155 O17069710 63 F 5.5 25 28 18.8 17.65 0 0
156 O07072077 59 M 11.36 24 22 15.4 16.5 0 0
157 O16068206 46 M 13.64 15 12 20.66 18.76 0 0
158 O17038557 53 M 0 20 25 18.53 16.55 0 0
159 O17065467 52 M 0 18 19 13.58 15.65 0 0
160 O07041260 68 F 7.5 16 15 16.7 18.42 0 0
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161 O12084715 51 M 0 22 25 12.8 13.8 0 0
162 O17067120 45 F 0 23 28 13.34 11.98 0 0
163 O06040938 47 F 5.5 30 30 15.56 15.87 0 0
164 O15043027 67 F 15.9 30 30 15.4 14.86 0 0
165 O17048276 53 F 0 25 25 16.33 18.75 0 0
166 O16035618 48 F 0 23 28 17.8 15.67 0 0
167 O16060106 50 F 0 30 30 12.89 17.65 0 0
168 O14045870 60 F 13.88 18 20 18.6 14.23 0 0
169 O97006854 52 F 0 21 19 15.38 16.8 0 0
170 O17052191 60 M 14.58 24 30 14.33 18.26 0 0
171 O17058240 52 M 0 15 18 17.45 20.86 0 0
172 O17050691 72 M 15.09 13 18 12.23 11.76 0 0
173 O15036382 55 F 0 23 24 17.34 11.23 0 0
174 O17012238 62 F 16.67 20 18 11.56 12.68 0 0
175 O17055115 50 F 0 23 28 14.57 19.43 0 0
176 O17055117 70 F 7.5 13 16 10.43 11.27 0 0
177 O17055113 60 F 7.5 24 23 16.82 13.42 0 0
178 O17055118 65 F 0 19 21 13.78 13.62 0 0
179 O17055108 75 F 15.63 21 27 12.89 15.82 0 0
180 O17055114 70 F 18.75 15 14 10.44 8.45 0 0
181 O08082947 52 M 0 28 30 18.92 20.17 0 0
182 O17055116 65 M 0 23 21 13.22 17.39 0 0
183 O09079502 42 M 0 30 28 17.99 17.32 0 0
184 O17003225 65 F 15.63 18 19 18.43 14.26 0 0
185 O17031915 65 F 9.1 25 25 12.88 16.75 0 0
186 O11049221 57 F 18.18 23 27 14.33 18.62 0 0
187 O17053428 40 F 0 30 30 21.8 19.84 0 0
188 O17021128 31 M 0 30 30 14.8 17.33 0 0
189 O17021136 35 M 2.3 29 25 13.55 20.22 0 0
190 O98023646 65 F 6.8 22 19 10.21 12.81 0 0
191 O17014058 51 M 0 28 19 18.2 18.66 0 0
109
192 O17013576 51 M 0 19 16 16.25 12.88 0 0
193 O17017782 49 M 0 25 25 15.3 16.44 0 0
194 O12007866 59 M 15.9 30 30 12.78 18.23 0 0
195 O17059033 50 M 0 16 17 15.05 18.54 0 0
196 O17009410 60 M 0 29 30 10.82 9.11 0 0
197 O17008950 65 F 2.8 23 19 12.73 12.06 0 0
198 O17054428 53 M 0 28 30 20.7 19.33 0 0
199 O17069389 59 F 15.63 30 30 12.87 14.84 0 0
200 O17069390 66 M 16.67 24 30 11.34 12.66 0 0
KEY USED IN MASTER DATA
KEY
Age
30-40 Group 1
41-50 Group 2
51-60 Group 3
>60 Group 4
Schirmers
<= 10 mm 1
>10 0
TBUT
< 6 secs 2
6-10 secs 1
>10 secs 0
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OCULAR SURFACE STAINING GRADE
Absent - Minimal 0
Mild 1
Moderate 2
Marked Severe 3
OSDI Grading
Normal 0
Mild 1
Moderate 2
Severe 3
Duration of Diabetes
1-5 years Cat 1
6-10 years Cat 2
11-20 years Cat 3
>20 years Cat 4
Diabetic Retinopathy Grading
No DR 0
Mild NPDR 1
Moderate NPDR 2
Severe NPDR 3
PDR 4
